Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspira Pathlab & DiagnosticsBOM:540788 -1.97%51 Gross Margin % is 75.51% as of Mar. 2026, which is 0% above its 10-year median of 75.44. GuruFocus rates BOM:540788 with a GF Score™ of 51/100 and a GF Value™ of ₹70.73 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 194 Medical Diagnostics & Research companies, Aspira Pathlab & Diagnostics ranks better than 81.96% on this metric.
BOM:540788's Gross Margin % is ranked better than 81.96% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 51.775
vs BOM:540788: 76.56
Aspira Pathlab & Diagnostics had a gross margin of 75.51% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Aspira Pathlab & Diagnostics had a gross margin of 75.51% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Aspira Pathlab & Diagnostics Gross Margin % Related Terms
Aspira Pathlab & Diagnostics Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540788 vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Aspira Pathlab & Diagnostics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Pathlab & Diagnostics Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Pathlab & Diagnostics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Aspira Pathlab & Diagnostics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Aspira Pathlab & Diagnostics (BOM:540788) has a Gross Margin % of 75.51% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Aspira Pathlab & Diagnostics and its competitors. This is near median its historical median of 75.44. Over the past decade, Aspira Pathlab & Diagnostics' Gross Margin % has ranged from 68.12 to 79.06. According to the industry distribution chart, Aspira Pathlab & Diagnostics ranks #35 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 18%.
Is Aspira Pathlab & Diagnostics' Gross Margin % too high?
Aspira Pathlab & Diagnostics' current Gross Margin % of 75.51% is near median its 10-year median of 75.44. Over the past 10 years, this metric has ranged from a low of 68.12 to a high of 79.06. The Medical Diagnostics & Research industry median Gross Margin % is 51.78. Aspira Pathlab & Diagnostics' value of 75.51% is 45.8% above this industry median. Based on the distribution chart, Aspira Pathlab & Diagnostics ranks #35 out of 194 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Aspira Pathlab & Diagnostics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Pathlab & Diagnostics' Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Pathlab & Diagnostics ranks #35 out of 194 companies for Gross Margin %. This places Aspira Pathlab & Diagnostics in the top 18% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 51.78. Aspira Pathlab & Diagnostics' value of 75.51% is 45.8% above this benchmark. Historically, Aspira Pathlab & Diagnostics' own Gross Margin % has ranged from 68.12 to 79.06 over the past decade. While the company's 10-year median is 75.44 vs. the industry median of 51.78, Aspira Pathlab & Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 51.78, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspira Pathlab & Diagnostics's current Gross Margin % of 75.51% is 45.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Aspira Pathlab & Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 51.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Pathlab & Diagnostics's current Gross Margin % is 75.51%, which is near median its own 10-year median of 75.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Pathlab & Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics (BOM:540788) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹70.73, compared to a current price of ₹106.90 — trading 51.1% above its estimated fair value. The current Gross Margin % is 75.51%, which is near median its 10-year median of 75.44 and 45.8% above the Medical Diagnostics & Research industry median of 51.78. Aspira Pathlab & Diagnostics' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Aspira Pathlab & Diagnostics (BOM:540788), the current Gross Margin % is 75.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Pathlab & Diagnostics (BOM:540788) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics stock appears to be overvalued.
The current stock price of ₹106.90 is trading 51.1% above its estimated GF Value™ of ₹70.73.
GuruFocus considers Aspira Pathlab & Diagnostics to be Significantly Overvalued.
Key valuation signals for BOM:540788:
Gross Margin %: 75.51% (near median its 10-year median of 75.44)
GF Value™: ₹70.73 vs. price of ₹106.90 (51.1% above fair value)
Industry Position: 45.8% above the Medical Diagnostics & Research median (#35 of 194)
No single metric tells the full story. See the BOM:540788 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Pathlab & Diagnostics Ltd is mainly engaged in pathology and related healthcare services. It operates laboratories that conduct a wide range of pathological investigations across branches such as biochemistry, hematology, histopathology, microbiology, immunochemistry, immunology, virology, cytology, and other pathological and radiological tests. The services offered include pathology tests, sonography, X-rays, and radiology. The company also provides various health packages like gynecology profiles, anemia profiles, monsoon profiles, coagulation tests, cancer screening packages, newborn screening and IEM panels, orthopedic profiles, allergy panels, and cardiac profiles. These comprehensive diagnostic services assist in disease diagnosis.
51GF Score
Get the complete analysis for BOM:540788
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540788 has been successfully added to your 
